RTP Mobile Logo
Submitted by nenadkesic@gmail.com on Mon, 10/23/2017 - 14:16
BCU117

Interview with Mark Robson, MD

Track 1: Side effects associated with PARP inhibitors
Track 2: Efficacy of olaparib for patients with BRCA germline-mutant metastatic triple-negative breast cancer (mTNBC)
Track 3: OlympiAD: A Phase III trial of olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation
Track 4: Somatic alterations in BRCA1/2 genes and response to PARP inhibitors
Track 5: BRCA testing for patients with BC
Track 6: Importance of genetic counseling for patients with germline mutations
Track 7: Clinical implications of the OlympiAD study results for patients with HER2-negative mBC
Track 8: TNT trial: Results of a Phase III study of carboplatin versus docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 mutation-associated BC
Track 9: Management of nausea and anemia associated with olaparib
Track 10: Case: A 49-year-old woman with BRCA-mutant mTNBC whose disease progresses through several lines of systemic therapy
Track 11: Mutational landscape of BC
Track 12: Ongoing trials of PARP inhibitors in the (neo)adjuvant setting
Track 13: Case: A 47-year-old woman with a 0.9-cm, Grade 2, ER/PR/HER2-positive invasive ductal carcinoma (IDC) receives adjuvant trastuzumab/paclitaxel
Track 14: APHINITY trial: Results of a Phase III study evaluating the addition of pertuzumab to chemotherapy and trastuzumab as adjuvant therapy for patients with HER2-positive early BC
Track 15: Adjuvant pertuzumab for patients with HER2-positive, node-positive mBC
Track 16: Case: A 65-year-old woman with ER-positive, HER2-negative mBC receives fulvestrant and palbociclib after disease relapse on exemestane
Track 17: Therapeutic options for patients with ER-positive, HER2-negative mBC after disease progression on a CDK4/6 inhibitor
Track 18: Targeting the androgen receptor in patients with mTNBC
Track 19: Case: A 54-year-old woman with bilateral ER/PR-positive, HER2-negative BC, 2 positive sentinel lymph nodes and a high genomic risk by the 70-gene assay
Track 20: Use of the 21-gene assay for patients with ER-positive, node-positive BC
Track 21: Case: A 49-year-old woman with BRCA mutation-positive mTNBC experiences rapid disease progression through several lines of therapy, including olaparib

Interview with Ian E Krop, MD, PhD

Track 1: Case: A 68-year-old woman with ER/PR-positive, HER2-negative, moderately differentiated IDC and 5 of 20 positive axillary nodes
Track 2: PALLAS: An ongoing Phase III trial evaluating the addition of palbociclib to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early BC
Track 3: Role of the 21-gene Recurrence Score® (RS) in the neoadjuvant setting
Track 4: Comparison of the 21-gene RS versus the 70-gene assay to determine benefit from chemotherapy in patients with ER-positive BC
Track 5: Updated ASCO clinical practice guidelines on the use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive BC
Track 6: MINDACT trial: Utility of the 70-gene assay in selecting patients with BC and 1 to 3 positive nodes for adjuvant chemotherapy
Track 7: ABC trials: TC versus anthracycline/taxane-based chemotherapy for high-risk HER2-negative BC
Track 8: Role of anthracyclines in patients with HER2-positive BC
Track 9: Case: A 56-year-old woman with ER/PR-positive, HER2-negative invasive lobular BC and bone metastases
Track 10: Emergence of ESR1 mutations in patients with ER-positive mBC
Track 11: Clinical significance of ESR1 mutations in patients receiving fulvestrant for ER-positive mBC
Track 12: Detection of ESR mutations in the plasma of patients with ER-positive BC
Track 13: CDK4/6 inhibitors as first-line therapy for patients with ER-positive, HER2-negative mBC
Track 14: Efficacy and tolerability of CDK4/6 inhibitors for patients with ER-positive, HER2-negative mBC
Track 15: Activity and tolerability of abemaciclib
Track 16: Case: A 52-year-old woman with a Stage I, ER/PR-negative, HER2-positive, poorly differentiated IDC
Track 17: APT trial: Results after a 7-year follow-up of adjuvant paclitaxel/trastuzumab for lower-risk, HER2-positive BC
Track 18: Results of the APHINITY trial evaluating adjuvant pertuzumab
Track 19: ExteNET: Results of a Phase III trial investigating neratinib after trastuzumab-based adjuvant therapy for patients with HER2-positive BC
Track 20: ATEMPT: An ongoing Phase II trial evaluating T-DM1 versus trastuzumab/paclitaxel for Stage I, HER2-positive BC
Track 21: Efficacy of enzalutamide in BC
Track 22: Case: A 40-year-old woman with mTNBC and a BRCA1 mutation receives olaparib on the OlympiAD trial
 
FACULTY:
 
Mark Robson, MD
Clinic Director
Clinical Genetics Service
Associate Attending Physician
Clinical Genetics and
Breast Cancer Medicine
Associate Member
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Medical College of
Cornell University
New York, New York
 
Ian E Krop, MD, PhD
Director of Clinical Research
Breast Oncology Center
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida